Eric Schmidt
Analyst
Cowen and Company
Analyst
Cantor
Analyst
Cantor Fitzgerald
Board Member
Relmada Therapeutics, Inc. (RLMD)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Cowen and Company
Analyst
Source not stated
Current -
Cantor
Analyst
Source not stated
Current -
Cantor Fitzgerald
Analyst
Source not stated
Current -
Current
-
Start not stated–2023-08-02
-
Start not stated–2023-09-05
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $490,000 | $5,279,677 |
| 2021 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $475,000 | $3,458,962 |
| 2020 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $440,000 | $2,483,819 |
| 2019 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $425,000 | $3,460,066 |
| 2018 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $201,232 | $2,588,989 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.